AB0514 Efficacy and Safety of Tofacitinib in Chinese Patients with Active Rheumatoid Arthritis: Subgroup Analysis from a Phase 3 Study of Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs

Y An,L Wang,Q Wu,K Kwok,Z Li

doi:10.1136/annrheumdis-2015-eular.4278

AB0514 Efficacy and Safety of Tofacitinib in Chinese Patients with Active Rheumatoid Arthritis: Subgroup Analysis from a Phase 3 Study of Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs

Y An, L Wang + Show 3 more

https://doi.org/10.1136/annrheumdis-2015-eular.4278

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2015
Citations: 2

Affiliation: Peking University People's Hospital, Peking University, Pfizer (United States), Pfizer (China)

#Month 6 #Chinese Pts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global Phase 3 ORAL Sync study (NCT00856544), tofacitinib improved disease activity in patients (pts)...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.